These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation. Nozaki Y, Kato Y, Uike K, Yamamura K, Kikuchi M, Yasuda M, Ohno S, Horie M, Murayama T, Kurebayashi N, Horigome H. Circ J; 2020 Jan 24; 84(2):226-234. PubMed ID: 31875585 [Abstract] [Full Text] [Related]
5. Catecholaminergic polymorphic ventricular tachycardia. Leenhardt A, Denjoy I, Guicheney P. Circ Arrhythm Electrophysiol; 2012 Oct 24; 5(5):1044-52. PubMed ID: 23022705 [No Abstract] [Full Text] [Related]
8. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia. Wangüemert Pérez F, Hernández Afonso JS, Groba Marco MDV, Caballero Dorta E, Álvarez Acosta L, Campuzano Larrea O, Pérez G, Brugada Terradellas J, Brugada Terradellas R. Rev Esp Cardiol (Engl Ed); 2018 Mar 24; 71(3):185-191. PubMed ID: 28789916 [Abstract] [Full Text] [Related]
9. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP, Cohen M, Hamilton RM, Pflaumer A, Kanter RJ, Potts JE, LaPage MJ, Collins KK, Gebauer RA, Temple JD, Batra AS, Erickson C, Miszczak-Knecht M, Kubuš P, Bar-Cohen Y, Kantoch M, Thomas VC, Hessling G, Anderson C, Young ML, Cabrera Ortega M, Lau YR, Johnsrude CL, Fournier A, Kannankeril PJ, Sanatani S. Circ Arrhythm Electrophysiol; 2015 Jun 24; 8(3):633-42. PubMed ID: 25713214 [Abstract] [Full Text] [Related]
11. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. Roston TM, Van Petegem F, Sanatani S. Curr Opin Cardiol; 2017 Jan 24; 32(1):78-85. PubMed ID: 27861184 [Abstract] [Full Text] [Related]
12. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia. Wangüemert F, Bosch Calero C, Pérez C, Campuzano O, Beltran-Alvarez P, Scornik FS, Iglesias A, Berne P, Allegue C, Ruiz Hernandez PM, Brugada J, Pérez GJ, Brugada R. Heart Rhythm; 2015 Jul 24; 12(7):1636-43. PubMed ID: 25814417 [Abstract] [Full Text] [Related]
13. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, Leong-Sit P, Gow RM, Green MS, Birnie DH, Krahn AD. Heart Rhythm; 2011 Jun 24; 8(6):864-71. PubMed ID: 21315846 [Abstract] [Full Text] [Related]
14. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome. Schneider HE, Steinmetz M, Krause U, Kriebel T, Ruschewski W, Paul T. Clin Res Cardiol; 2013 Jan 24; 102(1):33-42. PubMed ID: 22821214 [Abstract] [Full Text] [Related]
15. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Mohamed U, Gollob MH, Gow RM, Krahn AD. Heart Rhythm; 2006 Dec 24; 3(12):1486-9. PubMed ID: 17161793 [No Abstract] [Full Text] [Related]
19. A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia. Bosch C, Campuzano O, Sarquella-Brugada G, Cesar S, Perez-Serra A, Coll M, Mademont I, Mates J, Del Olmo B, Iglesias A, Brugada J, Petersen V, Brugada R. Forensic Sci Int; 2017 Jan 24; 270():173-177. PubMed ID: 27988446 [Abstract] [Full Text] [Related]